Innovent & Eli Lilly's Type 2 Diabetes Drug Lowers HbA1c, Scores Early Win

Preliminary results from Innovent Biologics' Phase II trial of mazdutide, a potential treatment for type 2 diabetes, showed the drug met its primary endpoint by successfully reducing HbA1c levels versus placebo after 20 weeks of treatment.